Delegat Group (DGL) H2 2026 earnings summary

Executive summary

• Achieved record global case sales of 3,320,000 in FY26, up 4% year-over-year, with strong growth across all major regions.

• Operating EBITDA reached a record $134.5 million, up 15% from the previous year.

• Operating NPAT rose 20% to $61.5 million, while reported NPAT declined 19% to $39.5 million due to fair value and non-cash adjustments.

• Net debt reduced by $51.8 million to $276.8 million, reflecting strengthened financial position and robust operating cash flows.

• Operating revenues reached $364.1 million, a 4% increase from FY25.

Financial highlights

• Sales revenue increased 4% to $360.6 million year-over-year.

• Operating EBIT rose 17% to $104.1 million, representing 29% of revenue.

• Operating gross profit grew 12% to $177.2 million, with gross margin improving to 49% from 45%.

• Record cash flows from operations at $110.5 million, up 5%.

• Fully imputed dividend of 22.0 cents per share declared, up 10% from the previous five years.

Outlook and guidance

• Asset base expected to support continued case sales growth through FY29.

• FY27 operating NPAT forecasted in the range of $62–$66 million, excluding US tariff refunds and non-operating items.

• FY27 global sales targeted at 3.4 million cases.

• Forecasting 5% growth in case sales over the next three years.

• Planned investment of $33.7 million in FY27 to support long-term growth.